Tenaya Therapeutics and Alnylam Pharmaceuticals entered a research collaboration in which Tenaya will deliver up to 15 novel genetic targets for cardiovascular disease discovery. The agreement includes a $10 million upfront payment and potential development, regulatory, and commercial milestones totaling up to $1.13 billion. Alnylam will lead subsequent development and commercialization for targets that progress, while Tenaya retains its internal gene‑therapy programs. The tie‑up signals big‑pharma interest in leveraging genetics and RNAi platforms to expand into cardiometabolic indications.